Tag: Drug stability studies,

How to Conduct Stability Studies for Controlled Drugs under Regulatory Guidelines Ensuring Compliance in Stability Studies for Controlled Drugs Introduction Controlled drugs, including narcotics and psychotropics, require stringent stability testing to ensure their safety, efficacy, and quality throughout their shelf life. Regulatory authorities, such as the US DEA, FDA, and international bodies, provide specific guidelines…

Read More “How to Conduct Stability Studies for Controlled Drugs under Regulatory Guidelines” »

How to Address Stability Testing for Products under Emergency Use Authorization (EUA) Stability Testing for Products under EUA: Navigating Regulatory Requirements Introduction Emergency Use Authorization (EUA) allows for the use of medical products during public health emergencies, even when they have not completed the standard approval process. Stability testing for products under EUA is crucial…

Read More “How to Address Stability Testing for Products under Emergency Use Authorization (EUA)” »

How to Implement Stability Testing for High-Risk Drug Products under Regulatory Guidelines Stability Testing for High-Risk Drug Products: Regulatory Compliance Guide Introduction High-risk drug products, such as controlled substances, cytotoxic agents, and biologics, require stringent stability testing to ensure their safety, efficacy, and quality. Regulatory authorities, including the US FDA, EMA, and WHO, have established…

Read More “How to Implement Stability Testing for High-Risk Drug Products under Regulatory Guidelines” »

How to Conduct Stability Studies for Drugs with Narrow Therapeutic Index under US FDA Guidelines Stability Studies for Drugs with Narrow Therapeutic Index: A Guide to US FDA Compliance Introduction Drugs with a narrow therapeutic index (NTI) have a small margin between therapeutic and toxic doses, making precise and rigorous stability testing essential to ensure…

Read More “How to Conduct Stability Studies for Drugs with Narrow Therapeutic Index under US FDA Guidelines” »

How to Implement Stability Testing for Non-Oral Dosage Forms in Compliance with Regulatory Guidelines Ensuring Compliance in Stability Testing for Non-Oral Dosage Forms Introduction Non-oral dosage forms, such as injectables, inhalers, transdermal patches, and ophthalmic solutions, present unique challenges in stability testing due to their distinct formulations, delivery mechanisms, and storage conditions. Ensuring compliance with…

Read More “How to Implement Stability Testing for Non-Oral Dosage Forms in Compliance with Regulatory Guidelines” »

How to Conduct Stability Testing for Biologics Under Biosimilar Regulatory Guidelines Stability Testing for Biologics: Adhering to Biosimilar Guidelines Introduction Biologics, including biosimilars, are complex molecules that require stringent stability testing to ensure their safety, efficacy, and quality. Stability studies for biosimilars must demonstrate that the product remains comparable to its reference biologic under specified…

Read More “How to Conduct Stability Testing for Biologics Under Biosimilar Regulatory Guidelines” »

How to Address Stability Testing for Breakthrough Therapy Drugs under FDA Guidelines Stability Testing for Breakthrough Therapy Drugs: Navigating FDA Requirements Introduction Breakthrough therapy drugs are designated by the FDA for expedited development and review due to their potential to provide substantial improvement over existing therapies for serious conditions. These drugs require specific stability testing…

Read More “How to Address Stability Testing for Breakthrough Therapy Drugs under FDA Guidelines” »

How to Implement ICH Q1A(R2) for Stability Testing of APIs and Drug Products Applying ICH Q1A(R2) Guidelines for Stability Testing of APIs and Drug Products Introduction Stability testing is a critical component of the drug development process, ensuring that Active Pharmaceutical Ingredients (APIs) and finished drug products maintain their intended quality, safety, and efficacy over…

Read More “How to Implement ICH Q1A(R2) for Stability Testing of APIs and Drug Products” »